Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WHR1 | P49842 | 5/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.49 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.47 |
| ▸ | TCF7L2 | Q9NQB0 | 2/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 3/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3319202 | 0.96 | WHR1 (0.51) | WHR1PDGFRBPDGFRATLR9TLR7 | |
| SCHEMBL3319575 | 0.93 | WHR1 (0.51) | WHR1PDGFRBPDGFRACTNNB1TCF7L2 | |
| SCHEMBL3318248 | 0.89 | WHR1 (0.52) | WHR1PDGFRBPDGFRATLR9TLR7 | |
| SCHEMBL2171759 | 0.87 | ADRA1A (0.53) | TP53MTORSMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL2170380 | 0.83 | WHR1 (0.47) | WHR1TP53MTORCYP1A2CYP3A4 | |
| SCHEMBL2170869 | 0.83 | ADRA1A (0.57) | TP53MTORSMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL2171433 | 0.81 | WHR1 (0.46) | WHR1TLR7TP53MTORCYP1A2 | |
| SCHEMBL7918343 | 0.81 | ADRA1A (0.55) | TP53MTORSMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL2170876 | 0.81 | WHR1 (0.43) | WHR1 | |
| SCHEMBL2171245 | 0.80 | WHR1 (0.43) | WHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346848-B1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2013-02-27 | — | — | EP | disclosed |
| US-8318749-B2 | Quinazoline derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318749-B2 | Quinazoline derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318749-B2 | Quinazoline derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20100125078-A1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-05-20 | — | — | US | disclosed |
| US-20100125078-A1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-05-20 | — | — | US | disclosed |
| US-20100125078-A1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125078-A1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | SLC6A3, OPRK1, HTR3A | WHR1 4280/4885PDGFRB 919/4885PDGFRA 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.